Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.

Dickinson, MichaelCherif, HonarFenaux, PierreMittelman, MosheVerma, AmitPortella, Maria Socorro OBurgess, PaulRamos, Pedro MarquesChoi, JeeaPlatzbecker, UweSUPPORT study investigators2025-01-072025-01-072018-10-10https://hdl.handle.net/10668/27323Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled study, investigated the platelet supportive effects of eltrombopag given concomitantly with azacitidine. International Prognostic Scoring System intermediate-1, intermediate-2, or high-risk MDS patients with baseline plateletsenAdultAgedAged, 80 and overAzacitidineBenzoatesDouble-Blind MethodFemaleHumansHydrazinesMaleMiddle AgedMyelodysplastic SyndromesPlatelet TransfusionPyrazolesRisk FactorsThrombocytopeniaAzacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.research article30305280open access10.1182/blood-2018-06-8552211528-0020PMC6337824https://ashpublications.org/blood/article-pdf/132/25/2629/1746801/blood855221.pdf